Company Name
APPLIED RESEARCH USING OMIC SCIENCES
Activity
Development of innovative molecular-based therapeutics for cancer
CIF
B63964506
Sector
BIOTECHNOLOGY
Address
Carrer Aribau 168, 1º 1ª - Barcelona
Web
www.aromics.es
EPM Joining Date
27/03/2025
Creation Date
02/09/2005
Founders Narcis Clavell, Carme Plasencia, Inmaculada Dalmau
Auditor
Capital Auditores
Investors email contact
info@aromics.es
Company profile
Aromics is a biotech company with 19 years of experience in developing innovative therapies for treatment of human diseases like cancer. We specialize in the application of OMIC sciences in designing and developing innovative drugs, able to control tumor progression and overcome drug resistance. With two recent patents and a disruptive approach, we are about to enter clinical trials to bring our solutions to market
On the Road to BME Growth
Relevant data
| (thousand of Euros) | 2024 | 2025* | 2026* | 2027* |
|---|---|---|---|---|
| Net worth | 4.727 | 12.741 | 12.756 | 50.211 |
| Net business turnover | - | - | - | 50.000 |
| Financial debt | 1.459 | 1.459 | 1.458 | 1.459 |
| Ebitda | 16 | 49 | 89 | 50.002 |
| Net Profit | 00,39 | 14 | 16 | 37.453 |
| Average number of employees | - | - | - | - |
| * Proyection | ||||
Business Model
Our business model focuses on developing and licensing innovative molecular-based therapies for cancer treatment. We create value through intellectual property generation, strategic collaborations with biotechs and pharma companies, and commercializing our technologies once demonstrated the proof of concept in humans (early clinical trials).
Competitive advantage
Our competitive advantage lies in disruptive targeting agents that bind on complex structural elements in nucleic acids to suppress the expression of key oncogenic proteins involved in tumor progression and drug resistance, This innovative approach offers greater specificity and efficacy in cancer treatment, with fewer side effects.
Scalability
Our technology is highly scalable, with potential applications across multiple types of solid tumors. This allows us to address a broad spectrum of unmet medical needs in the field of oncology.
